New alliance with Gilead Sciences is ‘transformative’
When Robert J. Alpern, M.D., dean of the School of Medicine, was asked recently to prepare a brief overview of the current state of drug discovery for a symposium at Yale’s West Campus, a familiar phrase came quickly to mind: “It was the best of times, it was the worst of times ...” It’s an apt description. On the one hand, we live in what some call the “post-Gleevec era,” a time when basic research conducted over decades is bearing fruit in the form of remarkably effective, targeted drugs.
Yale’s picks to beat cancer: a pair of aces
It has been an eventful December for the advancement of basic and translational cancer research at Yale. On the 13th, Yale University announced that Joseph Schlessinger, Ph.D., a world-renowned scientist with an unparalleled track record of identifying molecular targets for novel anticancer drugs, was named the first director of the University’s new Cancer Biology Institute (CBI), one of five major interdisciplinary research initiatives located on Yale’s West Campus. Just a week before, Thomas